Results 41 to 50 of about 6,578,993 (340)
A virtual approach to evaluate therapies for management of multiple myeloma induced bone disease: Modelling Therapies for Multiple Myeloma Induced Bone Disease [PDF]
, 2015 Multiple myeloma bone disease is devastating for patients and a major cause of morbidity. The disease leads to bone destruction by inhibiting osteoblast activity while stimulating osteoclast activity.
Fagan, Michael J. +2 more
core +2 more sources
Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine, 2019 BACKGROUND Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T‐cell therapy that targets B‐cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma. METHODS In this phase 1 study involving patients with
N. Raje +22 more
semanticscholar +1 more source
Extracellular Vesicles in Hematological Malignancies: From Biomarkers to Therapeutic Tools
Diagnostics, 2020 Small extracellular vesicles (EVs) are a heterogenous group of lipid particles released by all cell types in physiological and pathological states.
Jihane Khalife +2 more
doaj +1 more source
Chromosome 1q21 abnormalities in multiple myeloma
Blood Cancer Journal, 2021 Gain of chromosome 1q (+1q) is one of the most common recurrent cytogenetic abnormalities in multiple myeloma (MM), occurring in approximately 40% of newly diagnosed cases.
T. Schmidt, R. Fonseca, S. Usmani
semanticscholar +1 more source
Experimental Hematology & Oncology, 2017 B cell lymphoma and multiple myeloma (MM) are the most common hematological malignancies which benefit from therapeutic monoclonal antibodies (mAbs)-based immunotherapies.
Li Zhang +4 more
doaj +1 more source
npj Precision Oncology, 2023 Optimal first-line treatment that enables deeper and longer remission is crucially important for newly diagnosed multiple myeloma (NDMM). In this study, we developed the machine learning (ML) models predicting overall survival (OS) or response of the ...
Sung-Soo Park +11 more
doaj +1 more source
Prognostic and predictive biomarker developments in multiple myeloma
Journal of Hematology & Oncology, 2021 New approaches to stratify multiple myeloma patients based on prognosis and therapeutic decision-making, or prediction, are needed since patients are currently managed in a similar manner regardless of individual risk factors or disease characteristics ...
C. Wallington-Beddoe, Rachel L. Mynott
semanticscholar +1 more source
Phagocytic plasma cells in a patient with multiple myeloma [PDF]
, 1995 Phagocytosis of blood cells by malignant plasma cells in multiple myeloma is an extremely rare condition. Here we present a 39-year-old woman with multiple myeloma.
Hagemeijer, A. (Anne) +3 more
core +1 more source
Oral selinexor–dexamethasone for triple-class refractory multiple myeloma [PDF]
New England Journal of Medicine, 2019 BACKGROUND Selinexor, a selective inhibitor of nuclear export compound that blocks exportin 1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, inhibits nuclear factor κB, and reduces oncoprotein messenger RNA ...
al., et, Vij, Ravi
core +3 more sources
Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation.
Cancer Discovery, 2021 The proteasome inhibitor bortezomib induces apoptosis in multiple myeloma cells and has transformed patient outcome. Using in vitro as well as in vivo immunodeficient and immunocompetent murine multiple myeloma models, we here show that bortezomib also ...
Annamaria Gullà +17 more
semanticscholar +1 more source